

Aktualisierung der S2k-Leitlinie „Aphthen und aphthoide Läsionen der Mund- und Rachenschleimhaut“

- [1] Jackowski J, Strietzel FP, Altenburg A, Beisel S, Haßkamp P, Hussein RJ, Kallinich T, Kötter I, Reichert T, Schmidt-Westhausen AM, Weichert W, Hanisch M, Bachmann HS. S2k-Leitlinie Diagnostik und Therapieoptionen von Aphthen und aphthoiden Läsionen der Mund- und Rachenschleimhaut (AWMF-Registernummer: 007-101). https://www.dgzmk.de/documents/10165/1373255/LL_007-101_S2k_Aphthen_lang_2023.pdf/f16a3cc9-2b83-4a41-99c5-277b0b20fcbc
- [2] Allison P, Franco E, Black M, Feine J. The role of professional diagnostic delay in the prognosis of upper aerodigestive tract carcinoma. *Oral Oncol.* 1998; 34: 147-153.
- [3] Kowalski LP, Carvalho AL (2001). Influence of time delay and clinical upstaging in the prognosis of head and neck cancer. *Oral Oncol.* 2001; 37 (1): 94-98. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11120489>
- [4] Hertrampf K, Kunkel M et al. S2k-Leitlinie Diagnostik und Management von Vorläuferläsionen des oralen Plattenepithelkarzinoms in der Zahn-, Mund- und Kieferheilkunde (AWMF-Register Nr. 007-092). https://register.awmf.org/assets/guidelines/007-092l_S2k_orale_Vorlaeuerlaesion_Plattenepithelkarzinom_2020-04_1.pdf
- [5] Worm M, Nast A, Zidane M, Eming R, Goebeler M, Hertl M, Hofmann S, Hunzelmann N, Kern JS, Kramer H, Orzechowski H-D, Pfeiffer C, Sárdy M, Schemmel D, Schmidt E, Schuster V, Sitaru C, Sticherling M, Zillikens D. S2k-Leitlinie „Diagnostik und Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids“. (AWMF-Registernummer 013-071) 2019. https://www.awmf.org/uploads/tx_szleitlinien/0133-071l_S2k_Diagnostik-Therapie-Pemphigus-vulgaris-foliaceus-bullose-Pemphigoids_2019-10.pdf
- [6] Schmidt E, Goebeler M, Hertl M, Sárdy M, Sitaru C, Eming R, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, Orzechowski HD, Pfeiffer C, Schuster V, Sporbeck B, Sticherling M, Worm M, Zillikens D, Nast A. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. *J Dtsch Dermatol Ges.* 2015; 13 (7): 713-721.
- [7] Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, Pfeiffer C, Schuster V, Zillikens D, Goebeler M, Hertl M, Nast A, Orzechowski HD, Sárdy M, Schmidt E, Sitaru C, Sporbeck B, Worm M. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. *J Dtsch Dermatol Ges.* 2015; 13 (8): 833-844.
- [8] Schmidt E, Nast A, et al. S2k-Leitlinie Diagnostik und Therapie des Schleimhautpemphigoids (AWMF-Registernummer: 013-102) 2022. https://register.awmf.org/assets/guidelines/013-102l_S2k_Diagnostik-Therapie-Schleimhautpemphigoid_2022-08.pdf
- [9] Pereira T dos S, Silva Alves Jde F, Gomes CC, Rocha do Nascimento A, Stoianoff MA, Gomez RS. Kinetics of oral colonization by *Candida* spp. During topical corticotherapy for oral lichen planus. *J Oral Pathol Med.* 2014; 43: 570-575.

- [10] Altenburg A, Micheli CK, Puttkammer M, Abdel-Naser MB, Zouboulis CC. The treatment of chronic recurrent oral aphthous ulcers. *Dtsch Arztebl Int.* 2014; 111: 665-673.
- [11] Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfrikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Ann Rheum Dis.* 2018; 77: 808-818. doi:10.1136/annrheumdis-2018-213225
- [12] Lynde CB, Bruce AJ, Rogers RS, 3rd. Successful treatment of complex aphthosis with colchicine and dapsone. *Arch Dermatol.* 2009; 145 (3): 273-276. doi:10.1001/archdermatol.2008.591
- [13] Sharquie, K.E., Najim, R.A., A-bu-Raghif, A.R. Dapsone in Behçet's disease: A double-blind, placebo-controlled, cross-over study. *J Dermatol.* 2002; 29 (5): 267-279.
- [14] Sharquie KE, Najim RA, Al-Hayani RK, Al-Nuaimy AA, Maroof DM. The therapeutic and prophylactic role of oral zinc sulfate in management of recurrent aphthous stomatitis (ras) in comparison with dapsone. *Saudi Med J.* 2008; 29: 734–738.
- [15] Mimura MAM, Hirota SK, Sugaya NN, Sanches Jr JA, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. *Clinics* 2009; 64 (3): 193-198.
- [16] Cabras M, Carrozzo M, Gambino A, Broccoletti R, Sciascia S, Baldovino S, Arduino PG. Value of colchicine a treatment for recurrent oral ulcers: a systematic review. *J Oral Pathol Med.* 2020; DOI: 10.1111/jop.13020
- [17] Orfanos CE, Garbe C (Hrsg.). *Therapie der Hautkrankheiten.* Springer-Verlag Berlin, Heidelberg, New York 2002; 2. Auflage: S 580.
- [18] Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. *N Engl J Med.* 2019; 381 (20):1918-1928.
- [19] Hatemi G, Melikoğlu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, Merkel PA, Calamia KT, Liu Z, Pineda L, Stevens RM, Yazici H, Yazici Y. Apremilast for Behçet's syndrome- a phase 2, placebo-controlled study. *N Engl J Med.* 2015; 372 (16): 1510-1518.
- [20] Hirahara L, Kirino Y, Soejima Y, Takeno M, Takase-Minegishi K, Yoshimi R, Takeuchi M, Mizuki N, Nakajima H. Efficacy and safety of apremilast for 3 months in Behçet's disease: a prospective observational study. *Modern Rheumatol* 2020, accepted manuscript. <https://doi.org/10.1080/14397595.2020.1830504>
- [21] Vieira M, Buffier S, Vautier M, le Joncour A, Jamilloux Y, Gerfaud-Valentin M, Bouillet L, Lazaro E, Barete S, Misery L, Gobert D, Goulenok T, Fain O, Sacre K, Sève P, Cacoub P, Comarmond C, Saadoun D. Apremilast in refractory Behçet's syndrome: a multicenter observational study. *Front Immunol.* 2021; 11: 1-7. Doi: 10.3389/fimmu.2020.626792
- [22] Deeks ED. Apremilast: a review in oral ulcers of Behçet's disease. *Drugs* 2020. <https://doi.org/10.1007/s40265-019-01253-3>.
- [23] Yazici H, Pazarli, H, Barnes, CG, Tuzun, Y, Ozyazgan, Y, Silman, A, Serdaroglu, S, Oguz, V, Yurdakul, S, Lovatt, GE et al. A controlled trial of azathioprine in Behcet's syndrome. *N Engl J Med.* 1990; 322 (5): 281-285. doi:10.1056/NEJM19900201322050
- [24] Masuda K, NakajimaA, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. *Lancet* 1989; 333: 1093-1096.

- [25] Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H. Short-term trial of etanercept in Behçet's disease: A double blind, placebo-controlled study. *J Rheumatol*. 2005; 32 (1): 98-105.
- [26] Ranganath SP, Pai A. Is optimal management of recurrent aphthous stomatitis possible? A reality check. *J Clin Diagn Res*. 2016; 10 (10): ZE08-ZE13. doi: 10.7800/JCDR/2016/19519.8643
- [27] Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. *Arch Dermatol*. 1998; 134 (8): 1010-1016.
- [28] Sakly A, De Wever B, Jutla B, Satia M, Bogaert JP. The safety and efficacy of AphtoFix® mouth ulcer cream in the management of recurrent aphthous stomatitis. *BMC Oral Health*. 2016 11; 16:17. doi: 10.1186/s12903-016-0177-0.
- [29] Alpsöy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: A randomized, placebo-controlled, double-blind study. *Arch Dermatol*. 1999; 135 (5): 529-32.
- [30] Rattan J, Schneider M, Arber N, Gorsky M, Dayan D. Sucralfate suspension as a treatment of recurrent aphthous stomatitis. *J Intern Med*. 1994; 236 (3): 341-343.
- [31] Altenburg A, Abdel-Naser MB, Seeber H, Abdallah M, Zouboulis CC. Practical aspects of management of recurrent aphthous stomatitis. *J Eur Acad Dermatol Venereol*. 2007; 21 (8): 1019-1026.
- [32] Alpsöy E. New Evidence-Based Treatment Approach in Behçet's Disease. *Patholog Res Int*. 2012; 871019. doi:10.1155/2012/871019
- [33] Altenburg A, Zouboulis CC. Current concepts in the treatment of recurrent aphthous stomatitis. *Skin Therapy Lett*. 2008; 13 (7): 1-4.
- [34] Graykowski EA, Kingman A. Double-blind trial of tetracycline in recurrent aphthous ulceration. *J Oral Pathol*. 1978; 7 (6): 376-382.
- [35] Suter VGA, Sjölund S, Bornstein MM. Effect of laser on pain relief and wound healing of recurrent aphthous stomatitis: a systematic review. *Lasers Med Sci*. 2017; 32 (4): 953-963.
- [36] Rocca JP, Zhao M, Fornaini C, Tan L, Zhao Z, Merigo E. Effect of laser irradiation on aphthae pain management: A four different wavelengths comparison. *J Photochem Photobiol B*. 2018; 189: 1-4. doi: 10.1016/j.jphotobiol.2018.09.016.
- [37] Fani MM, EbrahimiH, Pourshahidi S, Aflaki E, Shafiee Sarvestani S. Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behçet's syndrome. *Iran Red Crescent Med J*. 2012; 14: 75-78.
- [38] Cabras M, Carrozzo M, Gambino A, Broccoletti R, Sciascia S, Baldovino S, Arduino PG. Value of colchicine a treatment for recurrent oral ulcers: a systematic review. *J Oral Pathol Med*. 2020; DOI: 10.1111/jop.13020
- [39] Schibler F, Heidemeyer K, Klötgen H-W, Keshavarmurthy V, Yawalkar N. Apremilast for the treatment of recalcitrant aphthous stomatitis. *JAAD Case Reports* 2017; 3 (5): 410-411.
- [40] Koilos AGA, Yawalkar N, Feusi A, Kündig T, Boyman O, Nilsson J. Apremilast in treatment-refractory recurrent aphthous stomatitis. *New Engl J Med*. 2019; 381 (20): 1975-1977.
- [41] Maloney NJ, Zhao J, Tegtmeyer K, Lee EY, Cheng K. Off-label studies on apremilast in dermatology: a review. *J Dermatolog Treat*. 2020; 31 (2): 131-140. doi: 10.1080/09546634.2019.1589641. Epub 2019 Apr 2 PMID: 30935262
- [42] Rote Liste® 2019. Rote Liste® Service GmbH, Frankfurt/M. 2019.

- [43] Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. *Dermatol Online J.* 2007; 13 (2).
- [44] Henricsson V, Axéll T. Treatment of recurrent aphthous ulcers with Aureomycin mouth rinse or Zendium dentifrice. *Acta Odontol Scand.* 1985; 43: 47-52.
- [45] Skulason S, Holbrook WP, Kristmundsdottir T. Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous ulcers. *Acta Odontol Scand.* 2009; 67: 25-29.
- [46] Golub LM, Lee H-M. Periodontal therapeutics: Current host-modulation agents and future directions. *Periodontol 2000.* 2020; 82: 186–204.